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Abstract
Introduction: Most patients are readily liberated from mechanical ventilation (MV) support, however, 10% - 15% of
patients experience failure to wean (FTW). FTW patients account for approximately 40% of all MV days and have
significantly worse clinical outcomes. MV induced inspiratory muscle weakness has been implicated as a
contributor to FTW and recent work has documented inspiratory muscle weakness in humans supported with MV.
Methods: We conducted a single center, single-blind, randomized controlled trial to test whether inspiratory
muscle strength training (IMST) would improve weaning outcome in FTW patients. Of 129 patients evaluated for
participation, 69 were enrolled and studied. 35 subjects were randomly assigned to the IMST condition and 34 to
the SHAM treatment. IMST was performed with a threshold inspiratory device, set at the highest pressure tolerated
and progressed daily. SHAM training provided a constant, low inspiratory pressure load. Subjects completed 4 sets
of 6-10 training breaths, 5 days per week. Subjects also performed progressively longer breathing trials daily per
protocol. The weaning criterion was 72 consecutive hours without MV support. Subjects were blinded to group
assignment, and were treated until weaned or 28 days.
Results: Groups were comparable on demographic and clinical variables at baseline. The IMST and SHAM
groups respectively received 41.9 ± 25.5 vs. 47.3 ± 33.0 days of MV support prior to starting intervention, P =
0.36. The IMST and SHAM groups participated in 9.7 ± 4.0 and 11.0 ± 4.8 training sessions, respectively, P = 0.09.
The SHAM group’s pre to post-training maximal inspiratory pressure (MIP) change was not significant (-43.5 ±
17.8 vs. -45.1 ± 19.5 cm H2O, P = 0.39), while the IMST group’s MIP increased (-44.4 ± 18.4 vs. -54.1 ± 17.8 cm
H2O, P < 0.0001). There were no adverse events observed during IMST or SHAM treatments. Twenty-five of 35
IMST subjects weaned (71%, 95% confidence interval (CI) = 55% to 84%), while 16 of 34 (47%, 95% CI = 31% to
63%) SHAM subjects weaned, P = .039. The number of patients needed to be treated for effect was 4 (95% CI =
2 to 80).
Conclusions: An IMST program can lead to increased MIP and improved weaning outcome in FTW patients
compared to SHAM treatment.
Trial Registration: ClinicalTrials.gov: NCT00419458
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Failure to wean (FTW) from mechanical ventilation
(MV) is a significant clinical and economic problem.
In 2003, approximately 300,00 patients required MV
support for more than 96 hours in the USA and the
estimated cost of these episodes was $16 billion [1].
The number of patients requiring long-term MV sup-
port is increasing five times as rapidly as the number
of hospital admissions [2] and many of these patients
experience FTW.
The etiology of FTW is often complex, but an imbal-
ance in the demand placed on the inspiratory muscles
used to generate inspiratory pressure during tidal
breathing and their maximal pressure generating cap-
ability (Pibr/Pimax) has been implicated as a major con-
tributor to this problem [3-5]. Numerous animal studies
have documented ventilator-induced diaphragm dys-
function following as little as six hours of controlled
MV [6-8], but less data examining the effects of MV on
the human diaphragm are available. Knisely et al. [9]
studied two children who had been ventilated for 7 and
45 days and qualitatively found profound atrophy of dia-
phragm muscle fibers following prolonged MV support.
Levine et al. [10] documented approximately 55% atro-
phy in human diaphragms following 19 to 56 hours of
controlled MV. Hermans et al. [11] recently reported
marked reductions in magnetically stimulated trans-
diaphragmatic pressure in humans in the first week of
MV support. Hussain et al. documented upregulation of
catabolic process in human diaphragms following 15 to
276 hours of controlled MV [12], and Jaber et al. docu-
mented a 32% reduction in endotracheal tube pressure
following magnetic diaphragm stimulation in humans
following six days of MV support [13].
As an elevated Pibr/Pimax ratio is thought to be a
major contributor to weaning failure [4,5] and MV has
been shown to rapidly cause diaphragm weakness in
humans, strength training the inspiratory muscles
emerges as a possible treatment for FTW. Preoperative
inspiratory muscle strength training (IMST) has been
shown to reduce the incidence of postoperative respira-
tory complications in high-risk cardiac surgery patients
[14] and has also been demonstrated to preserve post-
operative inspiratory muscle strength following major
abdominal surgery [15].
We [16] and others [17,18] have published successful
case series and Caruso et al. published an unsuccessful
[19] trial examining the effect of IMST on weaning
outcome in FTW patients, but to date no adequately
powered, randomized trial examining the effect of
IMST on weaning outcome exists. We hypothesized
that an IMST program, grounded in accepted princi-
ples of muscle strength training [20], coupled with
progressively lengthening breathing trials (BT) would
improve weaning outcome compared with the SHAM
condition.
Materials and methods
After approval from the University of Florida Health
Center Institutional Review Board (Federal wide Assur-
ance FWA00005790), written informed consent was
obtained from the patients or their legally designated
surrogates. The trial was registered on Clinical Trials
number NCT00419458. Patients were recruited from the
adult medical, general surgical and burn ICUs of Shands
Hospital at the University of Florida. Censuses of
patients who were supported with MV were regularly
queried and patients who had FTW with usual care
were identified. Subjects were considered a FTW case
when the patient failed to wean with usual care. Entry
and exclusion criteria are shown in Table 1.
Subjects were studied from February 2004 until Febru-
ary 2009. The protocol was a single-blinded design with
SHAM treatment. Subjects were blinded to their group
assignment. Randomization was performed with a com-
puterized random number generator and group assign-
ments were sealed in opaque envelopes. Subjects were
not randomized until they failed the initial BT.
Maximal inspiratory pressure measurement
Maximal inspiratory pressure (MIP) was measured on
the first day of participation, every Monday and on days
when the subjects attempted a 12-hour aerosol tracheot-
omy collar (ATC) trial. MIP was measured using the
method of Caruso et al. [21]. Briefly, a one-way valve
was attached to the patient’s tracheostomy tube that
allowed exhalation but blocked inspiration. The valve
was connected to an electronic recording manometer
and the patient was vigorously encouraged to inhale and
exhale as forcefully as possible for 20 seconds. MIP
measurements were repeated three times with a two-
minute rest period with MV support between each
attempt; the most negative value was recorded.
Inspiratory muscle strength training
IMST was performed five days per week (Monday to
Friday) with a threshold inspiratory muscle trainer
(Threshold PEP; Respironics Inc; Murrysville, PA, USA),
which provided a threshold inspiratory pressure load
between -4 and -20 cmH2O. The Threshold PEP device
is marketed as an expiratory positive pressure device,
but can provide an inspiratory threshold load if one
inspires through the exhalation port. An inspiratory
threshold training device is commercially available
(Threshold IMT; Respironics Inc; Murrysville, PA,
USA), but we found that many patients were unable to
open the poppet valve at the lowest pressure setting (8
cmH2O) on the Threshold IMT device. When
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the MV and the IMST device was attached to their tra-
cheostomy tube with the cuff inflated. Subjects breathed
room air during IMST. Subjects performed four sets of
6 to 10 breaths per day, with two minutes of rest with
MV support between each set. The training device was
set to the highest pressure setting that the subject could
consistently open during inspiration, and was progressed
daily as tolerated. Subjects were instructed to inhale and
exhale as forcefully as possible during the IMST breaths.
The IMST training program was based on clinical
experience obtained prior to initiating this trial. Respira-
tory pressures at the tracheostomy tube were monitored
during IMST and SHAM training with CO2SMO Plus
respiratory monitors with Analysis Plus software
(Respironics Inc; Murrysville, PA, USA) interfaced to a
laptop computer.
SHAM training
The SHAM group used a resistive inspiratory muscle
training device (Pflex; Respironics Inc; Murrysville, PA,
USA) set on the largest opening. The Pflex device had a
3 mm hole drilled into the body, which further reduced
the pressure required to generate airflow. Subjects per-
formed SHAM training by being removed from the ven-
tilator circuit and the training device was attached to
the tracheostomy tube. Subjects breathed room air dur-
ing SHAM treatment. Subjects performed four sets of 6
to 10 breaths, five days per week, and were instructed to
breathe with long, slow inspiratory and expiratory efforts
during training. SHAM subjects were given two minutes
of rest with MV support between each set. IMST and
SHAM treatments were normally conducted between
07.30 am and 09.00 am, Monday through Friday.
Breathing trials
All subjects participated in progressively lengthening
BTs with reduced or no MV support. Three types of BT
w e r eu s e d :A T C ,c o n t i n u o u s positive airway pressure
(CPAP) and reduced pressure support trials. Trials were
conducted seven days per week, usually commencing
around 09.00 am and only one trial per day was
attempted. The initial BT was an ATC trial, and patients
were allowed to breathe without MV support as long as
tolerated. Subjects who tolerated this initial ATC trial
for 72 hours were considered weaned and were not stu-
died. Criteria for terminating BT included: 30 beats/min
or more increase in heart rate, systolic blood pressure
above 180 mmHg or below 90 mmHg, oxygen-hemoglo-
bin saturation (SPO2) below 90% for five minutes,
respiratory rate above 35 breaths/min for five minutes,
serious dysrhythmias, if the patient requested to be
returned to MV support or there was clinical evidence
of respiratory distress (substernal retraction and sterno-
cleidomastoid retraction, paradoxical breathing, or
diaphoresis).
Table 1 Entry and exclusionary criteria
Age 18 years or older
Adequate gas exchange as indicated by a PaO2 above 60 mmHg while breathing with an FIO2 of 0.50 or less
Be medically stable and ready to be weaned from the ventilator as determined by the attending physician
Hemodynamically stable for 24 hours prior to participation or requiring only minimal intravenous pressor agents (dobutamine or dopamine ≤ 5
mcg/kg/min, phenyleprine ≤ 1 mcg/kg/min)
Be able to follow simple verbal directions related to inspiratory muscle strength testing and training
Receiving assist control or SIMV or pressure support ventilation via a tracheostomy, with SIMV ≤ 6 breaths/min, pressure support ventilation ≤ 15 cm
H2O and PEEP ≤ 10 cmH2O
Unable to sustain unsupported breathing for at least 72 consecutive hours following resolution of factor(s) precipitating respiratory failure
Demonstrate normal hemidiaphragm positions on X-ray
Not have any progressive neuromuscular disease such as amyotrophic lateral sclerosis, muscular dystrophy, multiple sclerosis, myasthenia gravis,o r
any other neuromuscular disorder that would interfere with responding to inspiratory muscle training
Have an anticipated life expectancy of at least 12 months
Have a core temperature between ≥36.5°C and ≤ 38.5°C
Not have a spinal cord injury above T8
Not have any skeletal pathology (scoliosis, flail chest, spinal instrumentation) that would seriously impair the movement of the chest wall and ribs
Not using any type of home MV support prior to hospitalization
Body mass index < 40 kg/m
2
Not require continuous sedative or analgesic agents that will depress respiratory drive or the ability to follow commands
No excessive secretions (requiring suctioning more than once every hour)
Not being considering for transfer to another hospital in the next
28 days
FiO2, fraction of inspired oxygen; MV, mechanical ventilation; PaO2, arterial pressure of oxygen; PEEP, positive end expiratory pressure; SIMV, synchronized
intermittent mandatory ventilation.
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two, three, four, six, nine, and twelve hours. The second
ATC trial was targeted for the step below the duration
the patient tolerated on their first ATC trial, not to
exceed six hours. For example, if a patient tolerated four
hours on the initial ATC trial, the second ATC trial
duration was three hours, the next four hours and so
on. When a subject failed an ATC trial, the next trial
was the same duration. If a subject was unable to parti-
cipate in ATC trials for several days, the ATC trial tar-
get duration was decreased by the number of steps
equal to the number of days missed. When subjects suc-
cessfully completed a 12-hour ATC trial, the next day
they progressed to breathing without MV support as tol-
erated. If they tolerated the ATC trial for 72 hours, they
were classified as weaned.
If the subject was unable to complete at least one
hour on the initial ATC trial, the next day a one-hour
CPAP trial was attempted. CPAP trials were progressed
b yo n eh o u rp e rd a yu n t i lr e a c h i n gt h r e eh o u r sa n d
then the patient began the ATC trial schedule as above.
If the patient was unable to complete the initial one-
hour CPAP trial, the next day they attempted a one-
hour reduced pressure support trial (no synchronized
intermittent mandatory ventilation breaths, about 50%
of their baseline pressure support and baseline positive
end expiratory pressure (PEEP)). If successful, the
reduced pressure support trial duration was increased
by one hour per day until reaching three hours where-
upon they then began the CPAP and ATC trial progres-
sions as detailed above.
Patients received usual nursing care during BT, but
rehabilitation activities were withheld during BT until
the patients could tolerate a six-hour ATC BT. Once
patients could tolerate a six-hour BT, rehabilitation
activity during BT was begun but reduced to approxi-
mately 50% of the normal duration and intensity until
weaning. Breathing data during BT were monitored with
ICU clinical bedside monitors and with a CO2SMO Plus
respiratory monitor with Analysis Plus software
(Respironics Inc; Murrysville, PA, USA) interfaced to a
laptop computer. Prior to commencing the first and
final BT, dynamic compliance and inspired and expired
airway resistance were measured with the CO2SMO
Plus respiratory monitors while the patients received
their baseline level of MV support.
Statistical analysis
Categorical variables were analyzed with Chi-square
tests. Between groups tests on continuous variables were
analyzed with independent samples Student t tests.
Within-group variables were analyzed with t tests for
paired measures. Repeated measures analysis of variance
(ANOVA) tests were used for variables with group, time
factors, and group × times interactions. Cell means con-
trasts were used to explore differences when significant
interactions were present in ANOVA. Statistical signifi-
cance was set at P< 0.05.
Results
The flow of subjects from evaluation to participation is
shown in the CONSORT diagram (Figure 1). The ran-
domization process resulted in groups that were equiva-
lent on demographic factors, reasons for respiratory
failure, treatment with renal replacement therapy, dura-
tion of MV prior to starting study intervention, duration
of the initial ATC trial to failure, MIP, and other prog-
nostic variables (Tables 2 and 3). Additionally, both
groups experienced similar comorbidities during hospi-
talization before intervention (Table 4), received similar
pharmacologic management during study intervention
(Table 5), experienced similar complications during the
study (Table 6), and underwent similar diagnostic and
therapeutic procedures during study intervention (Table
7 ) .O fn o t e ,4 3 %o ft h eI M S Ts u b j e c t sa n d2 9 %o f
SHAM subjects were dialysis dependent. Dialysis depen-
dency has been associated with a reduced wean rate
[22,23].
Six subjects did not fail during the initial ATC trial
and were weaned without further intervention. These
subjects were not randomized to treatment groups and
were not included in the analysis. Three IMST subjects
died during the 28-day treatment period, one withdrew
from the study and two patients were transferred to
other facilities before completing 28 days of treatment.
These six subjects were classified as weaning failures.
Three subjects in the SHAM group died during the 28-
day treatment period and three subjects were transferred
to other facilities before completing 28 days. These six
subjects were also classified as weaning failures.
Excluding the initial BT, the IMST group performed
330 trials and the SHAM group performed 382 trials.
The IMST and SHAM groups successfully completed
77.0% and 73.0% of the BT, respectively (P = 0.23).
The IMST and SHAM groups participated in 9.7 ±
4.0 and 11.0 ± 4.8 strength and SHAM training ses-
sions, respectively (P = 0.09). The mean training pres-
sure setting on the IMST device was 7.2 ± 2.6 vs. 12.8
±3 . 6c m H 2O for the initial and final training bouts,
respectively (P< 0.0001, Table 3). The SHAM group’s
modified training device was set at the largest orifice
(lowest resistance setting) for all sessions. The IMST
group developed -9.54 ± 3.70 and -14.52 ± 4.59
cmH2O of inspiratory pressure at the tracheotomy
tube during the initial and final IMST bouts (P =
0.0004). Corresponding training pressure values for the
SHAM group were -3.10 ± 1.54 and -3.36 ± 2.08
cmH2O( P = 0.86). The treatment × group interaction
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(P< 0.0001). The SHAM group’s pre to post-training
MIP change was not significant (-43.5 ± 17.8 vs. -45.1
±1 9 . 5c m H 2O, P = 0.39), while the IMST group’sM I P
increased (-44.4 ± 18.4 vs. -54.1 ± 17.8, cmH2O, P<
0.0001). There were no adverse events observed during
IMST or SHAM treatments.
Twenty-five of 35 IMST subjects weaned (71%, 95%
confidence interval (CI) = 55% to 84%), while 16 of 34
(47%, 95% CI = 31% to 63%) SHAM subjects weaned (P
= 0.039). The number of patients needed to be treated
for effect was 4 (95% CI = 2 to 80).
In order to further explore the role of MIP changes in
weaning outcome, we performed a post-hoc analysis on
MIP using weaning outcome as the independent
measure. The pre- and post-training MIP measures for
the weaning success (n = 41) and failure (n = 28) groups
were respectively; -44.0 ± 20.2 and -53.5 ± 20.7 cmH2O
versus -43.9 ± 14.8 and -43.9 ± 15.0 cmH2O. A repeated
measures ANOVA revealed a significant outcome ×
time interaction and the change in MIP for the success-
fully weaned group was significantly greater than the
failure to wean group (P< 0.0001).
Discussion
Our primary findings were that the IMST rehabilitation
program rapidly improved MIP and improved weaning
outcome compared with the SHAM condition. The
weaning rate (47%) achieved by the SHAM group was
comparable with usual care conditions as reported in
Figure 1 CONSORT diagram.
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patients [24-26].
Other workers have shown that MIP is a poor predic-
tor of extubation success [27-31]. Several differences
between this study and the studies that found MIP to be
a poor predictor of extubation outcome must be
acknowledged: 1) studies that have shown MIP to be a
poor predictor of extubation outcome examined intu-
bated patients in the acute phase of MV support [28,31],
whereas our subjects had received MV support for
approximately six weeks prior to starting intervention
and all of our patients had tracheotomies; 2) our selec-
tion criteria identified patients who had FTW because
of inspiratory muscle weakness that was amenable to
strength training; and 3) none of the studies that have
evaluated MIP as an extubation predictor used any type
of strength training program to increase MIP. Investiga-
tors have found that higher values of MIP are associated
with improved weaning outcome in chronic FTW
patients. Yang [31] reported in a cross-sectional study
that the Pibr/Pimax ratio of successfully weaned patients
was lower than FTW patients. Carlucci et al. [5] have
recently shown in an observational study with a group
of long-term FTW patients similar to ours, that patients
who eventually weaned, improved their MIP, and low-
ered the Pibr/Pimax ratio, while those who FTW did not.
Our findings also support a role for increased MIP in
improved weaning outcomes.
We propose that respiratory muscle weakness is a
greater contributor to failed weaning than fatigue. Dur-
ing failed BTs in FTW patients, respiratory distress is
often clinically described as “fatigue”. However, several
authors have reported heightened respiratory muscle
activity during failed BTs compared with stable respira-
tory muscle activity among patients who successfully
completed BTs. For example, Teixeira et al. [32] mea-
sured a 50% increase in the work of breathing of FTW
patients over the course of failed BTs, whereas success-
ful patients maintained a constant work of breathing
during the trials. Jubran et al. [33] reported similar find-
ings and an absence of low-frequency fatigue during
failed BT.
Alternatively, we hypothesize that inspiratory muscle
weakness initiates a high proportional ventilatory drive
requirement during unassisted BT, when weakened
inspiratory muscles must generate increased muscle ten-
sion in order to adequately ventilate the lungs. During
MV support, a relatively low motor drive elicits large,
ventilator-assisted tidal volume breaths. When an
unsupported BT begins, a discrepancy between the ele-
vated respiratory drive and afferent lung volume feed-
back can lead to an increased awareness of respiratory
effort [34]. Perceived feedback errors will be addressed
by further increases in respiratory motor drive, but the
feedback discrepancy cannot be corrected by a highly-
driven, weakened inspiratory pump that generates insuf-
ficient volume feedback [35].
Ongoing efferent-afferent feedback errors propel a
positive feedback loop, resulting in the progressively
higher levels of respiratory drive, inspiratory esophageal
pressure, and work of breathing reported by others, and
Table 2 Primary admission medical and surgical
diagnoses
Medical diagnosis IMST SHAM TOTAL
Cardiovascular
Acute congestive heart failure 1 . 1
Myocardial infarct or unstable angina 1 . 1
Respiratory
Adult respiratory distress syndrome 3 . 3
Interstitial disease 1 . 1
Pneumothorax . 1 1
Pulmonary vasculitis . 1 1
Neurological
Acute intracranial hemorrhage 1 . 1
Gastrointestinal
Pancreatitis 1 1 2
Infectious/metabolic
Sepsis with shock 2 2 4
TOTAL MEDICAL PATIENTS 10 5 15
Surgical diagnosis IMST SHAM TOTAL
Cardiovascular
Abdominal aortic aneurysm repair 2 2 4
Dissecting/ruptured aorta 1 1 2
Cardiac valve replacement . 1 1
Peripheral artery bypass graft 1 . 1
Multiple simultaneous procedures . 2 2
Other cardiovascular surgical procedures 2 . 2
Gastrointestinal
Esophageal surgery - for neoplasm 5 2 7
Esophageal surgery - not for neoplasm 1 1 2
Gastrointestinal surgery - for neoplasm . 1 1
Gastrointestinal surgery - not for neoplasm 6 6 12
Hepatobiliary surgery - for neoplasm 3 1 4
Hepatobiliary surgery - not for neoplasm 1 . 1
Neurological
Craniotomy, not for neoplasm . 4 4
Spinal surgery . 2 2
Spinal cord injury . 1 1
Orthopedic
Orthopedic surgery, not hip replacement . 2 2
Multiple simultaneous procedures . 1 1
Miscellaneous
Liver transplantation 2 1 3
Full-thickness burns/skin grafting 1 1 2
TOTAL SURGICAL PATIENTS 25 29 54
IMST, inspiratory muscle strength training.
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IMST n = 35 SHAM n =3 4 P value
Age (years) 65.6 ± 11.7 65.1 ± 10.7 0.86
Gender (male/female) 16/19 15/19 0.42
Number of smokers
Pack * years smoking history
12
54 ± 28
11
50 ± 30
0.86
0.72
Pre-albumin at study start
(mg/dL)
15.3 ± 6.6 15.4 ± 6.3 0.96
MV support days to start of study intervention 41.9 ± 25.5 47.3 ± 33.0 0.36
Total MV support days from hospital admission until end
of study participation
57.3 ± 29.5 63.5 ± 34.0 0.46
Total study days 14.4 ± 8.1 18.0 ± 8.8 0.10
SAPS II at study start 33.5 ± 8.6 33.0 ± 8.6 0.83
Dynamic compliance
(ml/cm H2O) n =2 6 n =2 7
aTr = 0.93
Pre-training 53.9 ± 18.3 53.8 ± 17.1
bTi = 0.19
Post-training 57.8 ± 19.5 57.1 ± 21.4
cTr × Ti = 0.91
Dynamic inspired airway resistance
(cm H2O/L/S) n =2 6 n =2 7
aTr = 0.70
Pre-training 7.8 ± 3.2 7.1 ± 3.0
bTi = 0.12
Post-training 7.7 ± 1.8 8.8 ± 3.0
cTr × Ti = 0.08
Dynamic expired airway resistance
(cm H2O/L/S) n =2 6 n =2 7
aTr = 0.74
Pre-training 8.1 ± 3.6 7.3 ± 3.1
bTi = 0.16
Post-training 7.9 ± 1.8 9.1 ± 3.4
cTr × Ti = 0.07
Renal function
Blood urea nitrogen
(mg/dL)
35.6 ± 15.6 37.6 ± 23.3 0.67
Creatinine (mg/dL)
(Includes subjects receiving renal replacement therapy)
1.1 ± 0.9 1.0 ± 0.7 0.74
Renal replacement therapy
n (%)
15 (43%) 10 (29%) 0.33
Mean daily fluid balance (ml) 118 ± 964 405 ± 573 0.14
Arterial blood gases on baseline MV support (initial day of study)
pH 7.41 ± 0.07 7.42 ± 0.06 0.68
PaCO2 (torr) 42.9 ± 7.4 40.3 ± 10.0 0.20
PaO2 (torr) 113.8 ± 48.0 108.8 ± 33.0 0.60
HCO3
- (mEq/L) 27.2 ± 5.1 26.0 ± 2.9 0.30
PaO2/FiO2 293 ± 125 278 ± 97 0.60
MV settings (initial day of study)
SIMV (br/min) 4.5 ± 3.7 3.8 ± 2.2 0.37
Pressure Support (cm H2O) 10.4 ± 1.8 10.0 ± 3.4 0.53
PEEP (cm H2O) 5.4 ± 1.0 5.8 ± 1.6 0.27
FiO2 0.40 ± 0.03 0.40 ± 0.004 0.77
Study-related activity
Initial ATC trial duration to failure (hours) 2.5 ± 2.1 3.1 ± 3.1 0.39
Number of study days patients were unable to participate 3.4 ± 5.0 3.8 ± 4.7 0.77
(% of study days) (16 ± 21%) (15 ± 18%) 0.87
Pressure setting on IMST device (cm H2O) Pre 7.2 ± 2.6 - < 0.0001
Post 12.8 ± 3.6
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positive feedback cycle progresses to high levels of
inspiratory muscle work, reflex sympathetic activation
can occur, with shunting of blood from the periphery to
the working respiratory muscles [37,38]. Elevated sym-
pathetic activity is a probable cause of the tachycardia,
hypertension, and diaphoresis frequently observed dur-
ing failed BT in FTW patients. IMST has been shown to
attenuate the sympathetic activation induced by high
intensity inspiratory muscle work [39].
Strengthening the inspiratory muscles theoretically
could correct the feedback discrepancy between respira-
tory drive and lung/chest expansion and may result in a
lower perception of breathing effort. The perception of
breathing effort has been experimentally altered by
manipulations of inspiratory muscle strength. Campbell
et al. [40] studied the perception of inspiring against
standard inspiratory resistive loads before and after
weakening the inspiratory muscles to about 30% of base-
line with neuromuscular blockade. In the weakened
state, subjects rated the effort of loaded breathing higher
than in the unblocked condition. We [41] studied the
effects of strengthening the inspiratory muscles on per-
ception of inspiratory effort and respiratory drive in
healthy subjects. Both the respiratory drive and the
effort of breathing against standard inspiratory resistive
loads were lower following a 50% improvement in MIP.
These findings support the hypothesis that the percep-
tion of inspiratory effort and respiratory drive are inver-
sely proportional to inspiratory muscle strength and
may help explain why an increased MIP contributed to
weaning.
Whenever severely debilitated patients undergo mus-
cle strength training, the possibility of exercise-induced
muscle damage must be considered. Human [42,43] stu-
dies have documented that long-term, high resistance
inspiratory loading can induce diaphragm muscle fiber
damage. Although we did not examine diaphragm sam-
ples for training-induced damage, we think that it is
unlikely that the IMST program induced muscle damage
for the following reasons: 1) the duration of muscle
loading during each IMST training session was approxi-
mately one minute per day. In contrast, animal and
Table 3 Demographic and medical data (Continued)
Pressure developed at tracheotomy tube during treatment (cmH2O)
aTr = 0.26
Pre-training -9.54 ± 3.70 -3.10 ± 1.54
bTi = 0.0003
Post-training -14.52 ± 4.59 -3.36 ± 2.08
cTr×Ti < 0.0001
Data are mean ± standard deviation.
ATC, aerosol tracheotomy collar; FiO2, fraction of inspired oxygen; HCO3
-, arterial bicarbonate concentration; IMST, inspiratory muscle strength training; MV,
mechanical ventilation; PaCO2, arterial pressure of carbon dioxide; PaO2, arterial pressure of oxygen; PaO2/FiO2, ratio of arterial pressure of oxygen to inspired
oxygen fraction; PEEP, positive end expiratory pressure; SAPS II, new simplified acute physiology score; SIMV, synchronized intermittent mandatory ventilation.
aTr, treatment factor,
bTi, time factor,
cTr × TI treatment × time interaction factor for two-way repeated measures analysis of variance on dynamic compliance,
dynamic inspired airway resistance, dynamic expired airway resistance and pressure developed at tracheotomy tube during training variables. All other variables
were tested with T tests for independent samples, paired samples or Chi-square tests.
Table 4 Comorbidities between hospital admission and
entering study
IMST SHAM
Cardiovascular
Angina 2 0
Atrial fibrillation 9 10
Bundle branch block 0 1
Arrhythmias requiring cardioversion 2 2
Congestive heart failure 7 5
Deep vein thrombosis 4 14
Cerebral vascular accident or intracranial hemorrhage 6 10
Myocardial infarction 6 5
Pacemaker 1 1
Pericarditis/endocarditis 0 1
Peripheral vascular disease/chronic wounds 3 7
Respiratory
Adult respiratory distress syndrome 2 4
Aspiration pneumonia 9 6
Bronchitis/bronchiectasis/chronic obstructive
pulmonary disease exacerbations
10 11
Pleural effusion 18 21
Pneumonia or tracheobronchitis 20 22
Pneumothorax 8 2
Pulmonary embolism 2 5
Hemothorax 3 2
Empyema 3 0
Respiratory arrest 1 2
Tracheal bleed 1 2
Bronchiolitis obliterans with organizing pneumonia 1 0
Cavitary respiratory lesions 1 1
Metabolic/Endocrine
Adrenal depletion 1 1
Diabetes mellitus 11 9
Hypothyroidism 5 6
Renal
Chronic renal failure (prior renal replacement
therapy-dependence)
20
Acute renal failure (new renal replacement therapy
dependence)
11 9
Renal insufficiency (no renal replacement therapy) 2 1
Infections
Specific Organisms:
Candida albicans 98
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with prolonged, high resistance loads, lasting 1.5 [44,45]
to 96 hours [46]. 2) Our IMST patients were able to
inspire against increasing inspiratory loads on a daily
basis. If the patients had been experiencing muscle sore-
ness and contractile fiber damage from IMST, one
would have expected diminished muscle performance,
rather than increasing performance.
Table 4 Comorbidities between hospital admission and
entering study (Continued)
Cytomegalovirus 44
Methicillin-resistant Staphylococcus aureus 13 17
Vancomycin-resistant enterococci 86
Pseudomonas 13 13
Acid-fast bacillus smear positive 1 0
Indwelling line-associated sepsis 2 7
Urinary tract infection 13 10
Sepsis with shock 18 13
Sepsis without shock 5 6
Gastrointestinal
Ascites 4 2
gastrointestinal hemorrhage 10 11
Clostrium difficile colitis 5 4
Ileus or gastroparesis 2 3
Necrotic bowel 4 1
Hepatic failure 0 1
Pancreatitis 5 1
Bowel perforation 1 1
Abdominal or peritoneal hematoma 5 3
Abdominal abscess 2 3
Necrotic gallbladder/cholelithiasis 3 2
Open abdomen 3 2
Abdominal compartment syndrome 0 1
Organ transplantation
Liver 2 1
Cardiac 0 1
Renal 1 0
Other
Cardiac arrest 6 7
Shock 0 2
New cancer diagnosis 11 9
Encephalitis 0 1
Encephalopathy (unspecified etiology) 5 1
Status epilepticus 0 1
Subacute or chronic fractures 1 3
Amputation 0 1
Wound 8 10
Wound or incisional dehiscence 4 5
Myoclonus 0 1
Critical illness myopathy (per physician) 3 1
Critical illness myopathy (per diagnostic test) 2 0
IMST, inspiratory muscle strength training.
Table 5 Drug use during intervention by group
IMST SHAM P value
Anabolic steroids
n (%) 6 (17%) 9 (26%) 0.34
Mean drug days 10.8 ± 4.8 15.6 ± 7.3 0.19
Antibacterial agents
n (%) 30 (86%) 29 (85%) 0.77
Mean drug days 28. ± 27.8 31.0 ± 23.5 0.71
Antiviral agents
n (%) 3 (9%) 1 (3%) -
Mean drug days 16.3 ± 4.0 6 -
Anti-arrhythmia agents
n (%) 13 (37%) 9 (26%) 0.34
Mean drug days 16.1 ± 11.0 14.8 ± 10.7 0.77
Anti-hypertensive agents
n (%) 17 (49%) 20 (59%) 0.47
Mean drug days 13.8 ± 11.7 15.3 ± 12.9 0.74
Bronchodilators
n (%) 16 (46%) 20 (59%) 0.28
Mean drug days 12.2 ± 7.5 17.3 ± 10.6 0.43
Corticosteroids
n (%) 16 (46%) 13 (38%) 0.53
Mean drug days 12.2 ± 7.5 10.8 ± 14.4 0.72
Diuretics
n (%) 21 (60%) 23 (68%) 0.47
Mean drug days 10.6 ± 6.6 11.0 ± 9.4 0.88
Anti-glycemic agents
n (%) 24 (69%) 28 (82%) 0.18
Mean drug days 13.5 ± 9.1 14.3 ± 11.1 0.77
Immune suppression agents
n (%) 3 (9%) 3 (9%) 0.70
Mean drug days 10.3 ± 14.4 3.7 ± 3.8 0.48
Neuromuscular blockers
n (%) 1 (3%) 1 (3%) -
Mean drug days 2.0 2.0 -
Narcotic analgesic agents
n (%) 30 (86%) 26 (76%) 0.33
Mean drug days 12.4 ± 9.8 13.9 ± 8.7 0.55
Sedatives
n (%) 27 (77%) 24 (71%) 0.42
Mean drug days 13.4 ± 13.0 11.3 ± 9.1 0.50
Vasopressors
n (%) 5 (14%) 8 (24%) 0.33
Mean drug days 3.8 ± 4.7 3.1 ± 3.8 0.78
Beta-blockers
n (%) 31 (89%) 29 (85%) 0.96
Mean drug days 19.6 ± 20.9 22.0 ± 21.6 0.66
IMST, inspiratory muscle strength training; n, number of subjects taking that
category of drug, followed by the percent of the group taking that drug
category. P values for proportions were calculated with chi square, corrected
with Yate’s correction for cells with five or less subjects. Mean drug days =
mean number (± standard deviation) of drug days for the subjects taking that
category of drugs. For example, if a patient took two different antibiotics for
four days, that patient would have accumulated eight drug days for the
antibiotic category. Drug days were tested with unpaired T tests.
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acknowledged. The weaning results were significant, but
this was a single site study with a relatively small sample
size. Our IMST method is not suitable for all FTW
patients. Patients must be sufficiently alert to cooperate
with IMST, and patients whose FTW etiology is not the
result of treatable inspiratory muscle weakness are unli-
kely to benefit from IMST. Our subjects were recruited
primarily from surgical ICUs, with approximately 22% of
the subjects treated in the medical ICU.
Conclusions
In conclusion, we found an improved MIP and weaning
outcome with IMST compared with SHAM training in
medically complex, long-term FTW patients. IMST is a
clinically practical and safe method to improve weaning
outcome in selected FTW patients.
Key messages
￿ IMST can rapidly increase MIP in medically com-
plex, long-term FTW patients.
￿ IMST, in conjunction with BT, can increase the
number of FTW patients weaned versus SHAM
training plus BT.
Abbreviations
ANOVA: analysis of variance; ATC: aerosol tracheotomy collar; BT: breathing
trials; CI: confidence interval; CPAP: continuous positive airway pressure; FTW:
failure to wean; IMST: inspiratory muscle strength training; MIP: maximal
inspiratory pressure; MV: mechanical ventilation; PEEP: positive end expiratory
pressure; Pibr/Pimax: ratio of inspiratory tidal breathing pressure to maximal
inspiratory pressure; SpO2: oxygen-hemoglobin saturation.
Table 6 Complications occurring during intervention
period
IMST SHAM
Cardiovascular
New angina diagnosis 1 1
Deep vein thrombosis 1 4
Myocardial infarction 0 2
Pericardial effusion 0 2
Hypertensive crisis 10 4
Respiratory
Aspiration pneumonia 3 1
Pneumonia or tracheobronchitis 13 13
Pneumothorax 0 1
Pleural effusion 9 3
Mucus plug 1 3
Other 2 7
Infections
Vancomycin-resistant enterococci 11 4
Methicillin-resistant staphylococcus aureus 64
Cytomegalovirus 12
Indwelling line-associated sepsis 6 5
Urinary tract infection 13 7
Sepsis with shock 6 2
Sepsis without shock 6 7
Other 10 9
Gastrointestinal
Ascites 1 0
Clostridium difficile colitis 20
Gastrointestinal hemorrhage 7 6
Hepatic failure 0 1
Renal
Acute renal insufficiency 1 0
Renal failure 2 1
Other
Tracheal bleeding 2 4
Cardiac arrest/cardiopulmonary resuscitation 2 4
Death 3 3
IMST, inspiratory muscle strength training.
Table 7 Diagnostic and therapeutic procedures
performed during study
IMST SHAM
Imaging
Computerized tomography scan 23 18
Echocardiogram 4 3
Endoscopy, lower 0 2
Endoscopy, upper 3 3
Diaphragm movement test 2 2
Electroencephalogram 0 1
Venous Doppler test 10 9
Other 7 6
Lines and Tubes
Abdominal drain 10 1
Central venous catheter 22 19
Chest tube 23 26
Gastrostomy tube 7 10
Jejunostomy/gastro jejunum tube 14 8
Peripherally inserted central catheter line 35 47
Other 28 33
Medical therapy
Bronchoscopy 26 42
Renal replacement treatments 111 62
Thoracentesis 3 0
Transfusion, blood (units) 81 132
Transfusion, other blood products 6 35
Wound debridement 1 1
Other 8 14
Surgery
Abdominal 3 1
Head/neck 1 3
Vascular 1 1
Thoracic 0 3
Other 3 5
IMST, inspiratory muscle strength training.
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